<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020136</url>
  </required_header>
  <id_info>
    <org_study_id>A4061063</org_study_id>
    <nct_id>NCT01020136</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Bioequivalence Study To Compare The Plasma Pharmacokinetics Of AG-013736 Polymorph Form IV Versus Market-Image Polymorph Form XLI Tablets In Healthy Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to show that 5 mg Form IV tablet of AG-013736 produces similar drug
      concentrations in plasma compared to 5 mg Form XLI tablet of AG-013736 after oral dosing
      under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish bioequivalence between Form IV and Form XLI of AG-013736 tablets
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the bioequivalence of test 5 mg market-image tablets of AG-013736 polymorph Form XLI to reference 5 mg tablets of AG- 013736 polymorph Form IV under fed conditions.</measure>
    <time_frame>3 days per period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of single dose AG-013736 when administered as polymorph Forms XLI and IV in healthy volunteer</measure>
    <time_frame>3 days per period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Sequence 1 (BABA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -&gt; A -&gt; B -&gt; A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 (ABAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -&gt; B-&gt; A -&gt; B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG-013736</intervention_name>
    <description>single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)</description>
    <arm_group_label>Sequence 1 (BABA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG-013736</intervention_name>
    <description>single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)</description>
    <arm_group_label>Sequence 2 (ABAB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 21 and 47 years, inclusive
             (Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12-lead electrocardiogram (ECG) and clinical laboratory tests)

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)

          -  An informed consent document signed and dated by the subject or a legally acceptable
             representative

        Exclusion Criteria:

          -  Evidence of significant disease of the blood, kidney, endocrine system, lungs,
             gastrointestinal, heart, liver, psychiatric, neurologic, or allergic (including drug
             allergies, but excluding season allergies)

          -  Use of tobacco- or nicotine- containing products (or a positive urine cotinine test).

          -  Pregnant or nursing females and females of childbearing potential including those with
             tubal ligation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>47 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061063&amp;StudyName=A%20Bioequivalence%20Study%20Of%20AG-013736%20Tablets%20Under%20Fed%20Conditions%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>April 21, 2010</last_update_submitted>
  <last_update_submitted_qc>April 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

